Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis

Abraham S Kanate¹, Alyssa DiGilio², Kwang W Ahn^{2

3}, Monzr Al Malki⁴, Eric Jacobsen⁵, Amir Steinberg⁶, Nelson Hamerschlak⁷, Mohamed Kharfan-Dabaja⁸, Rachel Salit⁹, Edward Ball¹⁰, Qaiser Bashir¹¹, Amanda Cashen¹², Daniel Couriel¹³, Jose Diez-Martin¹⁴, Emmanuel Katsanis¹⁵, Yulia Linhares¹⁶, Shahram Mori¹⁷, Richard Nash¹⁸, Attaphol Pawarode¹⁹, Miguel-Angel Perales²⁰, Colin D Phipps²¹, Carol Richman²², Bipin N Savani²³, Michael Y Shapira²⁴, Patrick Stiff²⁵, Roger Strair^{26

27}, Timothy S Fenske^{26

27}, Sonali M Smith²⁸, Anna Sureda²⁹, Horatiu Olteanu³⁰, Mehdi Hamadani²

Affiliations

¹ Osborn Hematopoietic Malignancy and Transplantation Program, West Virginia University, Morgantown, WV, USA.
² CIBMTR (Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
³ Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, WI, USA.
⁴ City of Hope National medical Center, Duarte, CA, USA.
⁵ Dana Farber Cancer Institute, Boston, MA, USA.
⁶ Department of Hematology-Oncology, Mount Sinai Hospital, New York, NY, USA.
⁷ Albert Einstein Hospital, Sao Paulo, Brazil.
⁸ Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
⁹ Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
¹⁰ University of California San Diego Medical Center, La Jolla, CA, USA.
¹¹ Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
¹² Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA.
¹³ Utah Blood and Marrow Transplant Program, Salt Lake City, UT, USA.
¹⁴ Hospital General Universitario Gregorio Maranon, Madrid, Spain.
¹⁵ University of Arizona Medical Center, Tucson, AZ, USA.
¹⁶ Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
¹⁷ Blood & Marrow Transplant Center, Florida Hospital Medical Group, Kissimmee, FL, USA.
¹⁸ Colorado Blood Cancer Institute, Denver, CO, USA.
¹⁹ Blood and Marrow Transplantation Program, Division of Hematology/Oncology, Department of Internal Medicine, The University of Michigan Medical School, Ann Arbor, MI, USA.
²⁰ Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
²¹ Department of Haematology, Singapore General Hospital, Singapore, Singapore.
²² University of California Davis Cancer Center, Sacramento, CA, USA.
²³ Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
²⁴ Department of Bone Marrow Transplant, Hadassah Medical Centre, Jerusalem, Israel.
²⁵ Loyola University Medical Center, Maywood, IL, USA.
²⁶ Robert Wood Johnson University Hospital, New Brunswick, NJ, USA.
²⁷ Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
²⁸ Section of Hematology/Oncology, The University of Chicago, Chicago, IL, USA.
²⁹ Haematology Department, Institut Català d'Oncologia - Hospitalet, Barcelona, Spain.
³⁰ Department of Pathology, Medical College of Wisconsin, Milwaukee, WI, USA.

PMID: 28771676
PMCID: PMC5796874
DOI: 10.1111/bjh.14879

Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis

Abraham S Kanate et al. Br J Haematol. 2018 Sep.

. 2018 Sep;182(6):916-920.

doi: 10.1111/bjh.14879. Epub 2017 Aug 2.

Authors

Affiliations

¹ Osborn Hematopoietic Malignancy and Transplantation Program, West Virginia University, Morgantown, WV, USA.
² CIBMTR (Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
³ Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, WI, USA.
⁴ City of Hope National medical Center, Duarte, CA, USA.
⁵ Dana Farber Cancer Institute, Boston, MA, USA.
⁶ Department of Hematology-Oncology, Mount Sinai Hospital, New York, NY, USA.
⁷ Albert Einstein Hospital, Sao Paulo, Brazil.
⁸ Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
⁹ Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
¹⁰ University of California San Diego Medical Center, La Jolla, CA, USA.
¹¹ Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
¹² Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA.
¹³ Utah Blood and Marrow Transplant Program, Salt Lake City, UT, USA.
¹⁴ Hospital General Universitario Gregorio Maranon, Madrid, Spain.
¹⁵ University of Arizona Medical Center, Tucson, AZ, USA.
¹⁶ Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
¹⁷ Blood & Marrow Transplant Center, Florida Hospital Medical Group, Kissimmee, FL, USA.
¹⁸ Colorado Blood Cancer Institute, Denver, CO, USA.
¹⁹ Blood and Marrow Transplantation Program, Division of Hematology/Oncology, Department of Internal Medicine, The University of Michigan Medical School, Ann Arbor, MI, USA.
²⁰ Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
²¹ Department of Haematology, Singapore General Hospital, Singapore, Singapore.
²² University of California Davis Cancer Center, Sacramento, CA, USA.
²³ Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
²⁴ Department of Bone Marrow Transplant, Hadassah Medical Centre, Jerusalem, Israel.
²⁵ Loyola University Medical Center, Maywood, IL, USA.
²⁶ Robert Wood Johnson University Hospital, New Brunswick, NJ, USA.
²⁷ Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
²⁸ Section of Hematology/Oncology, The University of Chicago, Chicago, IL, USA.
²⁹ Haematology Department, Institut Català d'Oncologia - Hospitalet, Barcelona, Spain.
³⁰ Department of Pathology, Medical College of Wisconsin, Milwaukee, WI, USA.

PMID: 28771676
PMCID: PMC5796874
DOI: 10.1111/bjh.14879

No abstract available

Keywords: allogeneic haematopoietic cell transplantation; extranodal NK/T-cell lymphoma; non-relapse mortality; relapse; survival.

PubMed Disclaimer

Figures

**Figure 1**
Cumulative incidence of non-relapse mortality (1A) and lymphoma relapse (1B) and Kaplan-Meir estimates of progression-free survival (1C) and overall survival (1D).

See this image and copyright information in PMC

References

1. Au WY, Weisenburger DD, Intragumtornchai T, Nakamura S, Kim WS, Sng I, Vose J, Armitage JO, Liang R International Peripheral T-Cell Lymphoma Project. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: A study of 136 cases from the international peripheral T-cell lymphoma project. Blood. 2009;113:3931–3937. - PubMed
1. Hari P, Raj RV, Olteanu H. Targeting CD38 in refractory extranodal natural killer Cell–T-cell lymphoma. N Engl J Med. 2016;375:1501–1502. - PubMed
1. Iqbal J, Weisenburger DD, Chowdhury A, Tsai MY, Srivastava G, Greiner TC, Kucuk C, Deffenbacher K, Vose J, Smith L, Au WY, Nakamura S, Seto M, Delabie J, Berger F, Loong F, Ko Y, Sng I, Liu X, Loughran TP, Armitage J, Chan WC. Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic gamma]delta] T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro. Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2011;25:348–358. - PubMed
1. Kim SJ, Choi JY, Hyun SH, Ki CS, Oh D, Ahn YC, Ko YH, Choi S, Jung SH, Khong PL, Tang T, Yan X, Lim ST, Kwong YL, Kim WS Asia Lymphoma Study Group. Risk stratification on the basis of deauville score on PET-CT and the presence of epstein-barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: A multicentre, retrospective analysis. The Lancet. Haematology. 2015;2:e66–74. - PubMed
1. Koo GC, Tan SY, Tang T, Poon SL, Allen GE, Tan L, Chong SC, Ong WS, Tay K, Tao M, Quek R, Loong S, Yeoh KW, Yap SP, Lee KA, Lim LC, Tan D, Goh C, Cutcutache I, Yu W, Ng CC, Rajasegaran V, Heng HL, Gan A, Ong CK, Rozen S, Tan P, Teh BT, Lim ST. Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma. Cancer Discovery. 2012;2:591–597. - PubMed

Publication types

Actions
Actions
Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis

Affiliations

Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis

Authors

Affiliations

Figures

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical